We analyzed the effect of age on highly active antiretroviral therapy efficacy and tolerance in 639 patients with human immunodeficiency virus (HIV) infection (99 of whom were aged 150 years, and 540 of whom were aged !50 years). Late testing, which was more frequent in the older age group, was the only independent factor associated with immunologic and clinical evolution of infection. Age 150 years was associated with earlier treatment discontinuation.
Clinicians will encounter increasing numbers of older HIVinfected patients in the coming years. Recent data from the French Hospital Database on HIV, a nationwide hospital-based cohort of 1100,000 HIV-infected patients, showed that 19% of the patients were 150 years old in 2003 [1] . This population is increasing over time because of the normal ageing of HIVinfected patients since HAART availability and because of late diagnosis of HIV infection in older patients [2] . Older patients have already been shown to be at high risk for late testing, because they are unaware that they are at risk in HIV infection, physicians are less likely to consider a diagnosis of HIV infection for older patients, and routine HIV testing is uncommon in this population [3] .
The immunovirological efficacy of antiretroviral therapy in this population has been debated, but since 1996, several studies have shown that age is neither related to treatment failure nor related to poorer immunologic restoration [3] [4] [5] [6] . Nevertheless, most of these studies provided data on small populations and did not take into account the "late testing" population, defined rience poorer immunovirological evolution of infection in response to HAART [7, 8] . This characteristic could, in part, explain the poorer immunovirological evolution of infection in response to HAART among older patients in some studies [7, 9] .
Furthermore, data on treatment tolerability in older patients is scarce [10] . Treatment tolerance could be worse in this population because of comorbidities and treatment interactions.
The aim of our study was to analyze the effect of age on HAART efficacy and tolerance in a large cohort of patients, taking late-testing situations into account.
Patients and methods. Information was collected from a large HIV reference center in Toulouse, France. This hospital (Hopital Purpan, Toulouse, France) maintains a prospective cohort of all patients with HIV infection who seek care in the center and provide written consent. The patients enter the cohort when they seek care in the center, regardless of their HIV disease history, and all previous clinical events, as well as a therapeutic history, are collected with appropriate dates. Demographic details, clinical events, a history of antiretroviral therapy, viral load data, and CD4 cell counts are collected at regular 3-6-month intervals during routine clinical assessment.
We selected antiretroviral-naive patients who initiated HAART from 1 January 1996 through 16 January 2006. The date of first HAART prescription was used as a baseline. HAART was defined as a combination of 2 nucleoside reversetranscriptase inhibitors plus either a protease inhibitor, with or without pharmacological booster, or a nonnucleoside reversetranscriptase inhibitor, or 3 nucleoside reverse-transcriptase inhibitors. We used an age cut off value of 50 years (!50 and у50 years old at baseline), as has previously been used by others [3, 4, 6, 7] .
Collected variables were sex, age at treatment initiation, most probable route of infection, date of HIV infection diagnosis, Centers for Disease Control and Prevention stage, date of first AIDS-defining event, hepatitis B or C virus coinfection, year of HAART initiation, type of first HAART (protease inhibitor, boosted protease inhibitor, nucleoside reverse-transcriptase inhibitor, or nonnucleoside reverse-transcriptase inhibitor), date of and reason for first treatment discontinuation (clinical, virologic failure, or poor tolerance), and CD4 cell count and viral load at the time of HIV infection diagnosis and at baseline ‫3ע(‬ months). Late HIV testing was defined as a CD4 cell count у200 cells/mm 3 ). In the P ! .001 multivariate analysis, the probability of having a CD4 cell count of !50 cells/mm 3 after 6 months of HAART was only associated with late testing (OR, 3.3; 95% CI, 1.6-6.7).
The proportion of patients who had a viral load р2.3 log copies/mL was similar in the 2 groups (66.7% vs. 68.6%). In the multivariate analysis, no characteristic was independently associated with this end point.
The proportion of clinical progression was similar in the 2 groups (8.1% vs. 5.7%), as was the median time before the clinical event (10.8 months [range, 4.6-32.8 months] and 7.1 months [range, 0.7-56.9 months] for older patients and younger patients, respectively). In the multivariate analysis, late testing was the only characteristic associated with clinical progression of infection (OR, 3.4; 95% CI, 1.5-8).
First HAART discontinuation was observed for 428 patients (67%) during follow-up, with no difference in the rate of discontinuation between the groups (older patients, 66.7%; younger patients, 67%). The median time before discontinuation was 6.4 months (interquartile range, 2.5-13.7 months) for older patients and 14.1 months (interquartile range, 4.9-31.0 months) for younger patients ( , by log-rank test). In the P ! .01 multivariate analysis, discontinuation of the first HAART regimen because of poor tolerance was independently associated with age (OR, 2; 95% CI, 1.1-3. Treatment discontinuations as the result of neurologic or psychiatric adverse effects were more frequent among older patients than younger patients (9.1% vs. 3%;
), as were P p .03 hematological adverse effects (13.6% vs. 5.5%;
). P p .03 Discussion. This study of an open-label prospective cohort included 639 antiretroviral-naive patients at the time of initiation of their first HAART regimen. Ninety-nine patients (15.5%) were aged 150 years. After 6 months of HAART, immunologic and virological evolution of infection did not differ between the 2 age groups, with 52.5% of the patients having a CD4 cell count 1350 cells/mm 3 and 67.7% having undetectable viral loads. Late testing was more frequent among the older group and was significantly associated with less frequent immunologic reconstitution and with clinical progression. First discontinuation of HAART was not more frequent among older patients, but when it occurred, it was earlier and more frequently related to poor tolerance.
The comparable efficacy of HAART in older patients has already been described in recent studies [4-6, 10, 11] . By contrast, some studies have shown that immunologic reconstitution was less frequent with increasing age [9, 12] , but these studies did not take the effect of late testing into account.
Our study has some limitations. Because our institution does not collect quantitative data on treatment adherence, this important information could not be analyzed. For this study, we selected patients initiating HAART in 1996 or after to maximize the number of patients. This long period is in part responsible for the missing values, because for those patients who were previously treated in another center, we may not have been able to collect pretherapeutic information. The missing data were equally distributed between groups, and we think that this should not be responsible for major biases. The high frequency of late testing in the older population has already been described [1, 11] , and we agree, as do others [6] , that earlier diagnosis of HIV infection is mandatory in older patients, because the use of HAART allows them to achieve immunovirological responses similar to those in younger patients.
